PIPELINE Pipeline Overview Selecta is working on two antigen-specific SVP™ platforms covering immune tolerance and immuno-stimulatory vaccines. Immune Tolerance Platform Tolerogenic Synthetic Vaccine Particles (SVP™) are designed to induce antigen-specific immune tolerance. Selecta researchers are working on applications in autoimmune diseases, allergies, and most importantly the inhibition of neutralizing anti-drug antibodies (ADA) to biologic therapy and protein replacement therapies for rare diseases. Immuno-stimulatory Vaccine Platform Stimulatory Synthetic Vaccine Particles (SVP™) activate immune responses to a wide array of relevant antigens, including small molecules, peptides, oligosaccharides, and proteins. These particles target humoral and cellular pathways of the immune system inducing robust antibody and cytolytic T cell responses. Selecta's pipeline includes a prophylactic vaccine for malaria and therapeutic vaccines in cancer, chronic infections and addiction. © 2015 Selecta Biosciences, Inc. | 480 Arsenal St., Building One, Watertown, MA 02472 | Phone: 617-923-1400 | Fax: 617-924-3454 | Email: info@selectabio.com Privacy Policy | Web site designed and developed by RainCastle Communications, Inc.